The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
Publications
An 84-Year-Old Physician With Progressive Dyspnea and Bilateral Upper Lobe Opacities.
Chest 2021 May;159;e325-e329 — 2021 May — e325-e329
Drug reaction with eosinophilia and systemic symptoms (DRESS) with severe and atypical lung involvement.
Radiology case reports 2020 Nov;15;2178-2182 — 2020 Nov — 2178-2182
Naproxen and the occurrence of eosinophilic pneumonia.
American family physician 1993 Nov 01;48;1023 — 1993 Nov 01 — 1023
Pulmonary infiltrates with eosinophilia due to naproxen.
Chest 1983 Feb;83;280-2 — 1983 Feb — 280-2
Pulmonary infiltrates associated with naproxen.
JAMA 1984 Jan 06;251;65-6 — 1984 Jan 06 — 65-6
Naproxen and pneumonitis.
JAMA 1984 Oct 12;252;1853 — 1984 Oct 12 — 1853
Pulmonary infiltrates and eosinophilia associated with naproxen.
British journal of rheumatology 1985 Aug;24;302-3 — 1985 Aug — 302-3
Pulmonary eosinophilia associated with naproxen therapy.
Journal of the Royal Society of Medicine 1987 Feb;80;120-1 — 1987 Feb — 120-1
Ogawa H, Kurashima K, Namura M, Kanaya H, Kawamura Y, Ohka T, Kurumaya H, Yasui M, Fujimura M, Matsuda T
Pulmonary infiltrates with eosinophilia due to naproxen.
Japanese journal of medicine 1991 Jan-Feb;30;32-4 — 1991 Jan-Feb — 32-4
Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports.
Archives of internal medicine 1992 Jul;152;1521-4 — 1992 Jul — 1521-4